About

advancing medicine. precisely.

BiomX is developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.

We develop natural and engineered phage cocktails as precision medicines to target and destroy specific harmful bacteria that are causative agents in chronic diseases

Executive Team

Jonathan Solomon

CEO & Board Member

Prior to his role in BiomX, Mr. Solomon was a co-founder, president, and CEO of ProClara (formerly NeuroPhage), which is pioneering an approach to treating neurodegenerative diseases. Under his leadership, the company raised more than $100 million and launched an ongoing clinical trial related to Alzheimer’s disease. Mr. Solomon holds a B.Sc. magna cum laude in Physics and Mathematics from the Hebrew University, an M.Sc. summa cum laude in Electrical Engineering from Tel Aviv University, and an M.B.A. with honors from the Harvard Business School.

Assaf Oron

CBO

Assaf Oron has served as chief business officer since January 2017. Prior to this position, he served for over a decade at Evogene Ltd. (NYSE:EVGN), an agriculture biotechnology company which utilizes a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. At Evogene, he worked in various roles such as executive vice president of corporate development and executive vice president of strategy and business development. From 2004 to 2006, Mr. Oron served as CEO of ChondroSite Ltd., a biotechnology company that develops engineered tissue products in the field of orthopedics. From 1999 to 2003, Mr. Oron was a senior project manager and strategic consultant at POC Ltd., a leading Israeli management consulting company. Mr. Oron holds an M.Sc. in Biology (bioinformatics) and a B.Sc. in Chemistry and Economics, both from Tel Aviv University.

Merav Bassan, PhD

CDO

Dr. Bassan was most recently Vice President Head of Translational Sciences at Teva Pharmaceutical Industries, Inc., where she was responsible for early stages of clinical development via translation from animal data to human. Prior to this role, Dr. Bassan served as Vice President of Project Leadership at Teva Pharmaceutical, where she managed project leaders overseeing end-to-end drug development at pre-clinical, PI-III and post marketing stages in multiple therapeutic areas, such as pain, oncology, women‘s health, endocrinology, GI, biosimilars and other areas. Overall, Dr. Bassan has over 20 years of leadership experience with clinical and drug development teams in her various roles at Teva Pharmaceutical and other smaller biotech companies. Dr. Bassan is also a member of the Israeli 8400 health network, a cross-sector network of leaders actualizing the global disruptive capabilities of Israel’s HealthTech ecosystem. Dr. Bassan holds a Ph.D. in Neuroscience from the Tel-Aviv University Sackler School of Medicine and completed a post-doctoral fellowship in Neuroscience at Harvard University.

Marina wolfson

CFO

Marina Wolfson has served as the Senior Vice President of Finance and Operations of the Company since December 2019. Ms. Wolfson’s experience includes working with large pharmaceutical and hi-tech companies, as well as venture capital funds. Prior to joining the Company, Ms. Wolfson worked as Vice President of Finance at BioView Ltd. (TASE) from 2010 to 2019 and a senior auditor at Ernst & Young, an international auditing and business advisory firm 2007 to 2010. Ms. Wolfson is a certified public accountant in Israel and holds a B.A in Economics and Accounting (with honors) and an MBA (with honors, specializing in finance) from Ben-Gurion University.

Inbal benjamini-elran

CHRO

Ms Benjamini-Elran has over 15 years of experience in executive HR roles in global and diverse environments. At Teva Pharmaceuticals Industries Inc (NYSE:TEVA) she served in various senior roles including Director of HR of the European HQ (Netherlands) and HR manager of R&D API division. Her most recent experience was as Head of HR at Herzog, one of the largest law firms in Israel and as an independent HR consultant, advising a variety of companies in the Israeli hi-tech and biotech sectors.  Ms. Benjamini-Elran holds an MBA from Bar-Ilan University and a BA in behavioral science from Ben-Gurion University.

Michael Billard

General Manager, U.S.

Mr. Michael Billard has over twenty-years of experience in biotech, pharma, and consumer product development. He served as VP, Project Execution at Adaptive Phage Therapeutic since September 2020, which was acquired by the Company in March 2024. Prior to that, he held senior leadership roles at Propella Therapeutics, Inc., Paragon Bioservices and DSM Nutritional Products (formerly Martek BioSciences) along with project management positions at MedImmune, Inc. and Baxter Healthcare Corporation. Mr. Billard earned his Master of Science in Biotechnology from Johns Hopkins University

Board of Directors

Russell G. Greig, Ph.D.

Chairman of the Board of Directors

Russell G. Greig, Ph.D. worked at GlaxoSmithKline for three decades, most recently as President of SR One, GlaxoSmithKline’s corporate venture group. Prior to joining SR One, he served as President of GlaxoSmithKline’s Pharmaceuticals International from 2003 to 2008 as well as on the GlaxoSmithKline corporate executive team. Currently, Dr. Greig serves as Chairman of MedEye Solutions in the Netherlands, eTheRNA in Belgium and Sanifit in Spain. He was previously Chairman of Ablynx in Belgium (acquired by Sanofi, France), Isconova in Sweden (acquired by Novavax, United States), Novagali in France (acquired by Santen, Japan) and Syntaxin in the United Kingdom (acquired by Ipsen, France), as well as board member of TiGenix in Belgium (acquired by Takeda, Japan).

Jonathan Leff

Director

Jonathan Leff is a Partner on the Therapeutics team at Deerfield and Chairman of the Deerfield Institute, and joined the Firm in 2013. He focuses on venture capital and structured investments in biotechnology and pharmaceuticals. Prior to Deerfield, for more than sixteen years, Mr. Leff was with Warburg Pincus, where he led the firm’s investment efforts in biotechnology and pharmaceuticals. He is a member of the Boards of several public and private healthcare companies as well as several not-for-profit organizations, including the Spinal Muscular Atrophy Foundation and the Columbia University Medical Center Board of Advisors, and has previously served as a director of the Reagan-Udall Foundation for the Food and Drug Administration. Mr. Leff has also been active in public policy discussions related to healthcare and medical innovation. He previously served as a member of the Executive Committee of the Board of the National Venture Capital Association (NVCA), where he led NVCA’s life sciences industry efforts as Chair of NVCA’s Medical Innovation and Competitiveness Coalition (NVCA-MedIC), and also previously served on the Board of the Biotechnology Innovation Organization. Mr. Leff holds an A.B. from Harvard University, an M.B.A. from Stanford University’s Graduate School of Business, and an M.S. in Biotechnology from Johns Hopkins University.

Alan Moses, MD

Director

Alan Moses, M.D., was co-founder and co-director of the Clinical Investigator Training Program at Beth Israel Deaconess-Harvard Medical School-MIT. Dr. Moses served as Senior Vice President and Chief Medical Officer of the Joslin Diabetes Center in Boston. He was appointed Professor of Medicine at Harvard Medical School. Over the course of 14 years at Novo Nordisk, Dr. Moses served in multiple roles, rising to the position of Senior Vice President and Global Chief Medical Officer. During his tenure there, Dr. Moses provided medical support to regulatory filings for the approval of 11 successful Novo Nordisk products. Dr. Moses earned his M.D. from the Washington University School of Medicine in St. Louis, worked at the National Institutes of Health and completed subspecialty clinical training in Endocrinology at Tufts New England Medical Center.

Greg Merril

Director

Mr. Greg Merril is a serial life-science entrepreneur, recognized by Ernst & Young as a regional Entrepreneur of the Year winner. He has served as Chair of several international phage therapy conferences. As prior founding CEO of Immersion Medical (NASDQ: IMMR) he led the creation of the world’s first commercially successful virtual reality surgical training simulators resulting in a company that was one of Maryland’s fastest revenue growth technology firms for four consecutive years. IMMR had peak market capitalization of over $1 billion. Greg has been recognized as a TEDMED Innovation Scholar for his work developing and commercializing head impact sensor technology to address the issue of sports-related traumatic brain injury. During his career Greg’s product developed efforts have been recognized twice as Innovation of the Year by the Consumer Electronic Association (CEA)/ Industrial Designers Society of America (IDSA). Other awards have included the 2015 International Sports Technology Award for Best Wearable Technology, and his previous company was selected as a Wall Street Journal Startup Company of the Year.

Eddie Williams

Director

Mr. Eddie Williams is a well-recognized, senior global life sciences executive with extensive boardroom and commercial operations experience. He most recently served as a Special Advisor to the Chief Executive Officer of Ascendis Pharma, Inc., and previously as their interim U.S. Chief Commercial Officer. Before joining Ascendis, Mr. Williams held key leadership positions, including Senior Vice President of biopharmaceuticals at Novo Nordisk Inc. Mr. Williams also served as the Vice President of Sales in the Respiratory and Dermatology Business Unit at Novartis Pharmaceuticals Corp. and held numerous sales and marketing positions of increasing responsibility for more than 20 years at Pharmacia & Upjohn Company, which was acquired by Pfizer in 2002. Mr. Williams currently serves on the board of directors of BioAtla Inc., and Boone Memorial Health, a non-profit hospital and health services organization Mr. Williams earned his B.S. in biology and chemistry from Marshall University.

Jesse Goodman, MD, MPH

Director

Jesse Goodman, M.D., M.P.H. is Professor of Medicine at Georgetown University and Director of the Center on Medical Product Access, Safety and Stewardship which focuses on science and policy to address public health needs including antimicrobial resistance. He is Attending Physician in Infectious Diseases at Georgetown University, Washington DC Veterans Administration and Walter Reed Medical Centers. He previously was Chief Scientist and Deputy Commissioner for Science and Public Health of the U.S. Food and Drug Administration (FDA), also serving as part of the government’s senior leadership for the 2009 influenza pandemic and other major public health responses and for the 2010 White House Medical Countermeasure Review. Prior to that, he directed FDA’s Center for Biologics Evaluation and Research (CBER) and before that, as Senior Advisor to the FDA Commissioner, co-chaired the U.S. Task Force to Combat Antimicrobial Resistance. Previously he was Professor of Medicine and Chief of Infectious Diseases at the University of Minnesota, where his laboratory isolated A. phagocytophilum, the causative agent of human granulocytic anaplasmosis. He has served on various CDC, NIH, DOD, CEPI and WHO Advisory Committees and serves on the Boards of the US Pharmacopeia, GSK and Intellia Therapeutics. He has been elected to the National Academy of Medicine of the National Academy of Sciences.

Jonathan Solomon

Director

Prior to his role in BiomX, Mr. Solomon was a co-founder, president, and CEO of ProClara (formerly NeuroPhage), which is pioneering an approach to treating neurodegenerative diseases. Under his leadership, the company raised more than $100 million and launched an ongoing clinical trial related to Alzheimer’s disease. Mr. Solomon holds a B.Sc. magna cum laude in Physics and Mathematics from the Hebrew University, an M.Sc. summa cum laude in Electrical Engineering from Tel Aviv University, and an M.B.A. with honors from the Harvard Business School.

Susan Blum

Director

Ms. Blum is the Chief Financial Officer of Melinta Therapeutics, LLC. (“Melinta”), a company focused on the development and commercialization of innovative therapies for acute and life-threatening illnesses. She joined Melinta in 2016 as the company’s Controller, and then served as Vice President of Finance & Chief Accounting Officer prior to being appointed to the CFO position in 2021. Prior to joining Melinta, Ms. Blum served as Corporate Controller at Textura Corporation from 2013 to 2016, supporting the company’s IPO and transformation into a publicly-traded organization. Ms. Blum also served in leadership roles at Orbitz Worldwide, Inc. (NYSE: OWW) from 2011 to 2013 and at Facet Biotech Corporation and PDL BioPharma, Inc. (Nasdaq: PDLI) from 2004 to 2010, where she was responsible for such functions as external reporting and related compliance, technical accounting and internal controls over financial reporting. Ms. Blum began her career in public accounting at Ernst & Young, where she spent nearly seven years working with a diverse client base ranging from large, public international engagements to development-stage enterprises. Ms. Blum is a Certified Public Accountant, currently serves as a member of the BioNJ Cybersecurity Committee and holds a B.S. in Business Commerce from Santa Clara University

Scientific Founders

Rotem Sorek, Ph.D

Professor Sorek leads the Microbial Genomics group in the Department of Molecular Genetics at the Weizmann Institute of Science. He is a world leader in phage genomics and CRISPR research, and also develops techniques for high resolution understanding of microbial transcriptomics and metatranscriptomics. Sorek holds a Ph.D. in Human Genomics from Tel Aviv University, and in his postdoc, studied microbial metagenomics at the Lawrence Berkeley National Laboratory. Prior to joining the Weizmann Institute, Sorek headed the Genomics Research Group at Compugen (Nasdaq:CGEN). Prof. Sorek is also an author of numerous scientific publications in top-tier journals, and an inventor of more than 35 patents. He has received multiple awards, including the 2012 Rubinowitz-Grossman Prize in Microbiology, the 2013 Teva Founders Award for young scientists, and the 2014 FEBS Anniversary Prize. In 2015, Sorek was elected as a member of the European Academy of Microbiology.

Eran Elinav, M.D, Ph.D

Professor Elinav is a senior scientist leading a research group in the Immunology Department at the Weizmann Institute of Science. Elinav has over 110 published articles and received several awards for his work, including the 2013 Alon Prize and the 2015 Rappaport Prize for outstanding biomedical research. Before joining the Weizmann Institute, Professor Elinav held an independent research position at the Institute for Gastroenterology and Liver Disease at the Tel Aviv Sourasky Medical Center. He Elinav completed his M.D. at the Hebrew University of Jerusalem Hadassah Medical Center summa cum laude, followed by internship, residency, clinical, and research positions at the Tel Aviv Medical Center Gastroenterology Institute. Elinav also has a Ph.D. in immunology from the Weizmann Institute of Science and served in a postdoctoral fellowship at the Yale University School of Medicine.

Timothy K. Lu, M.D, Ph.D

Professor Lu is an associate professor leading the Synthetic Biology Group in the Department of Electrical Engineering and Computer Science and the Department of Biological Engineering at MIT. Prof. Lu graduated with an S.B. and M.Eng. from MIT, and an M.D./Ph.D. from the Harvard-MIT Health Sciences and Technology program. He is also a core member of the MIT Synthetic Biology Center and a co-founder of multiple biotechnology companies that develop innovative diagnostic and therapeutic technologies for human health. Prof. Lu is a recipient of the ACS Synthetic Biology Young Investigator Award, the Biochemical Engineering Journal Young Investigator Award, the NIH New Innovator Award, the Presidential Early Career Award for Scientists and Engineers, and the Ellison Medical Foundation New Scholar in Aging Award, among others.

Our Partners

biomx’s corporate presentation

Updated May 2024

Sign up for the latest updates

Join our mailing list to receive company updates
delivered to your inbox
Join the list